Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY

Pearce, Fiona A.; Lim, Sean H.; Bythell, Mary; Lanyon, Peter; Hogg, Rachel; Taylor, Adam; Powter, Gillian; Cooke, Graham S.; Ward, Helen; Chilcot, Joseph; Thomas, Helen; Mumford, Lisa; McAdoo, Stephen P.; Pettigrew, Gavin J.; Lightstone, Liz; Willicombe, Michelle

doi:10.1016/S2665-9913(23)00160-1

All Outputs (2)

Long-term outcomes (beyond 5 years) of liver transplant recipients--a transatlantic multicenter study (2023)
Journal Article
Palaniyappan, N., Peach, E., Pearce, F., Dhaliwal, A., Campos-Varela, I., Cant, M. R., …Aravinthan, A. D. (2024). Long-term outcomes (beyond 5 years) of liver transplant recipients--a transatlantic multicenter study. Liver Transplantation, 30(2), 170-181. https://doi.org/10.1097/LVT.0000000000000244

The long-term (>5y) outcomes following liver transplantation (LT) have not been extensively reported. The aim was to evaluate outcomes of LT recipients who have survived the first 5 years. A multicenter retrospective analysis of prospectively collect... Read More about Long-term outcomes (beyond 5 years) of liver transplant recipients--a transatlantic multicenter study.

Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY (2023)
Journal Article
Pearce, F. A., Lim, S. H., Bythell, M., Lanyon, P., Hogg, R., Taylor, A., Powter, G., Cooke, G. S., Ward, H., Chilcot, J., Thomas, H., Mumford, L., McAdoo, S. P., Pettigrew, G. J., Lightstone, L., & Willicombe, M. (2023). Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. The Lancet Rheumatology, 5(8), E461-E473. https://doi.org/10.1016/S2665-9913%2823%2900160-1

Background: In the UK, additional COVID-19 vaccine booster doses and treatments are offered to people who are immunosuppressed to protect against severe COVID-19, but how best to choose the individuals that receive these vaccine booster doses and tre... Read More about Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.